Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanraplenib (GS-9876) in Active Rheumatoid Arthritis
NCT02885181Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of lanraplenib in rheumatoid arthritis (RA), sponsored by Gilead Sciences. Started Sep 2016; status: completed.
02
Drugs
lanraplenib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02885181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885181.